Health · Pharma & Biotech · 1 hr ago
Racura gets Israeli approval for first site in leukaemia drug trial
Sheba Medical Center in Israel approved the first site for Racura Oncology’s EMILI trial of its drug RC220.
The trial will test the drug in adults with acute myeloid leukaemia that has returned or resisted treatment.
AML is an aggressive cancer of the blood and bone marrow.
Some patients may be able to receive a potentially curative stem cell transplant, but their leukaemia generally needs to be controlled first.
The trial will test whether seven days of RC220 can bring the cancer into remission and help patients proceed to transplant.
Racura expects to activate the site by the end of 2026 and enrol and treat the first patient in early 2027.
The company plans to seek approval to open more sites in Europe, the United States and Australia in 2027, and will use the trial’s early stage to help choose a dose for its Phase III stage.
Sheba Medical Center in Israel has granted site ethics approval for Racura Oncology’s first site in its EMILI trial of RC220 for relapsed or refractory acute myeloid leukaemia.
Racura expects to activate the site and start the trial by the end of 2026.
The company expects the first patient to be enrolled and treated in the first quarter of 2027.
The Phase IIb/III trial will test whether a seven-day course of RC220 can bring the disease into remission, potentially allowing patients to proceed to a stem cell transplant.
Racura plans to open additional trial sites in Europe, the United States and Australia in 2027, subject to regulatory approvals and feasibility.
- Who
- Racura Oncology and Sheba Medical Center. The trial is for adults with relapsed or refractory acute myeloid leukaemia.
- What
- Sheba granted site ethics approval for the first site in Racura’s EMILI Phase IIb/III trial of RC220.
- When
- Approval was reported on 18 November 2026. Trial initiation is expected by the end of 2026, with the first patient expected in Q1 2027.
- Where
- Sheba Medical Center, Israel.
- Why
- The trial will assess whether RC220 can bring the leukaemia into remission, potentially enabling patients to proceed to a stem cell transplant.
This story does not have two clearly opposing sides.
Stockhead reported that Sheba Medical Center had granted site ethics approval for the trial’s first site.
Racura expects to complete site activation and start the trial.
Racura expects to enrol and treat the first patient.
Racura plans to activate additional sites in Europe, the United States and Australia, subject to regulatory approvals and feasibility.
- Trial
- EMILI Phase IIb/III
- Drug
- RC220, Racura’s formulation of bisantrene
- First site
- Sheba Medical Center, Israel
- First patient
- Expected in Q1 2027
- Additional sites
- Europe, United States and Australia in 2027
What people are saying
EMILI will open first at Sheba, where Professor Arnon Nagler and his team have studied bisantrene in AML patients for many years
With this approval, our focus now turns to activating Sheba with other sites to follow, with the aim of generating the data needed to select the right RC220 dose for the pivotal Phase III stage.